Outstanding Recoveries
- Home
- Outstanding Recoveries
Verdicts & Settlements
Since Milberg’s founding in 1965, the firm has recovered more than $50 billion for our clients while prompting meaningful changes in corporate governance.
Filter By
Select Practice Area
-
See More$3.4 Billion Settlement – Avandia Marketing, Sales Practices, and Products Liability Litigation
In re Avandia Marketing, Sales Practices, and Products Liability Litigation, MDL 1871 (U.S. District Court for the Eastern District of Pennsylvania)Milberg attorneys were appointed to the Plaintiffs Steering Committee and served on the Discovery and Media Sub-Committees on behalf of thousands of patients who took the Type 2 diabetes drug Avandia, alleging the manufacturer failed to disclose the known and increased risk of heart attack and cardiac death. GlaxoSmithKline set aside $3.4 billion in 2011 to settle lawsuits. -
See More$90 Million Settlement – Royal Dutch/Shell Transport ERISA Litigation
In re Royal Dutch/Shell Transport ERISA Litigation, No. 04-1398 (D.N.J.)An ERISA breach of fiduciary duty class action against the Royal Dutch/Shell Oil Group of Companies on behalf of certain of the companies’ U.S. employee investment plan participants. The $90 million settlement included important provisions regarding the monitoring and training of individuals appointed to be ERISA fiduciaries. -
See More$85 Million Settlement – Mason v. Medline
Mason v. Medline, No. 07-05615 (N.D. Ill.)Milberg successfully represented a healthcare worker in a False Claims Act case against his former employer, Medline Industries, Inc., one of the nation’s largest suppliers of medical and surgical products, along with its charitable arm, The Medline Foundation. The suit alleged that Medline engaged in a widespread illegal kickback scheme targeting hospitals and other healthcare providers that purchase medical products paid for by federal healthcare programs. Milberg pursued the case on a non-intervened basis and recovered $85 million on behalf of the federal government — one of the largest settlements of a False Claims Act case in which the government declined to intervene. -
See More$138 Million Settlement – Biovail Corp. Securities Litigation
In re Biovail Corp. Securities Litigation, No. 03-8917 (S.D.N.Y.)Milberg, representing Local 282 Welfare Trust Fund and serving as Co-Lead Counsel, litigated this securities action alleging that defendants made misleading statements concerning Biovail’s financial results and its drug, Cardizem LA. Following substantial discovery, including depositions across the U.S. and Canada, Milberg obtained a $138 million settlement for the class, and Biovail agreed to institute significant corporate governance changes. -
See More$1+ Billion Settlement – NASDAQ Market-Makers Antitrust Litigation
In re NASDAQ Market-Makers Antitrust Litigation, No. 94-3996 (S.D.N.Y.)Milberg served as Co-Lead Counsel for a class of investors alleging that NASDAQ market-makers set wide spreads pursuant to an industry-wide conspiracy in one of the largest and most important antitrust cases in recent history. Following more than three years of litigation, the case settled for over $1 billion.
